Beckman Coulter, Inc. dev elops and markets instruments, biochemicals, software, and products that simplify and automate laboratory processes. The company’s products support biomedical analysis at every stage of the fight against disease—from cutting-edge medical research to patient blood testing.

In 2004, the company generated $2.4 billion in sales, with 70% coming from the clinical diagnostics market and 30% from the biomedical research market. Diluted earnings per share (excluding special charges/credits) were $0.82.

In 2010, the company generated $3.7 billion in sales, with 87.6% coming from the clinical diagnostics market and 12.4% from the biomedical research market.

Beckman was reorganized in 1988 following its spin-off from SmithKline Beckman. In 1998, the company’s name was changed to Beckman Coulter, Inc., reflecting its 1997 merger with Coulter.